Showing 4501-4510 of 8828 results for "".
- A New Look for Merz Aestheticshttps://practicaldermatology.com/news/a-new-look-for-merz-aesthetics/2461352/Merz Aesthetics has launched a new corporate visual identity to underscore the company's commitment to putting the definition of beauty back into the hands of the individual through a vibrant and distinct color palette along with strong and joyful photography. The new visual identit
- CHMP Recommends Adtralza (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe ADhttps://practicaldermatology.com/news/chmp-recommends-adtralza-tralokinumab-for-the-treatment-of-adolescents-with-moderate-to-severe-ad/2461351/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is recommending extending the approval of LEO Pharma’s Adtralza (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic
- Positive Dupixent Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe ADhttps://practicaldermatology.com/news/positive-dupixent-phase-3-data-in-children-aged-6-months-to-5-years-with-moderate-to-severe-ad/2461349/Dupixent significantly improved skin clearance, and reduced itch and overall disease severity in children as young as 6 months old, according to a new Phase 3 trial in the Lancet. Thes
- Almirall's Tildrakizumab Demonstrates Meaningful Sleep Improvement in People Living with Psoriasishttps://practicaldermatology.com/news/almiralls-tildrakizumab-demonstrates-meaningful-sleep-improvement-in-people-living-with-psoriasis/2461345/During the 31st EADV (European Association of Dermatology and Venereology) Congress, Almirall S.A shared the results from TRIBUTE, an interventional phase IV clinical study that resembled real-life clinical practice. In this study, Ilumetri (tildrakizumab) is&n
- Meet the Cast of Allergan Aesthetics and BOTOX Cosmetic's New 'See Yourself' Campaignhttps://practicaldermatology.com/news/meet-the-cast-of-allergan-aesthetics-and-botox-cosmetics-new-see-yourself-campaign/2461344/Allergan Aesthetics is unveiling the 25 real patients – of all forms, genders, ethnicities and backgrounds – who were selected to participate in the latest iteration of the BOTOX Cosmetic 'See Yourself' campaign. A After receiving nearly 20,000 submis
- FDA Approves BMS' Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-bms-sotyktu-for-plaque-psoriasis/2461341/The FDA has approved Bristol Myers Squibb Sotyktu (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sotyktu is not recom
- Sklip Gets Approval to Test Skin Cancer Triage at Home Using AIhttps://practicaldermatology.com/news/sklip-gets-approval-to-test-skin-cancer-triage-at-home-using-ai/2461336/Sklip System AI for safe, effective and regulated consumer use
- Artemis Health, Zerigo Health Partner to Help Employers and Health Plans Better Evaluate and Manage Chronic Autoimmune Skin Conditionshttps://practicaldermatology.com/news/artemis-health-zerigo-health-partner-to-help-employers-and-health-plans-better-evaluate-and-manage-chronic-autoimmune-skin-conditions/2461335/Artemis Health and Zerigo Health are joining forces to helps employers, advisors, and health plans evaluate and manage benefits for their members with chronic autoimmune skin conditions such as psoriasis and atopic dermatitis. “Benefits leaders are inundated by hundreds of point s
- DREAM Initiative from Allergan Aesthetics, SkinBetter Science Launches CARE Curriculumhttps://practicaldermatology.com/news/dream-initiative-from-allergan-skinbetter-science-launches-care-curriculum/2461334/The DREAM Initiative®, developed by Allergan Aesthetics and skinbetter science®, has supported the development of a racial equity curriculum for dermatology residency programs. The Curriculum f
- Cutera: Aviclear Hits 1,000 Treatment Markhttps://practicaldermatology.com/news/cutera-aviclear-hits-1000-treatment-mark/2461333/More than 1,000 AviClear laser acne treatments have been performed in the United States, Cutera reports. AviClear is FDA-cleared for the treatment of mild, moderate and severe acne. Additionally, AviClear recently received approval from Health Canada for the treatment of all severities